Chapel Hill, NC, United States of America

Chunqin Deng

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: United Therapeutics Corporation. Active years: 2023-2026.

USPTO Granted Patents = 4 

% Patents Active = 75.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2023-2026

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations in Lung Disease Treatment by Chunqin Deng

Introduction

Chunqin Deng is an accomplished inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of medicine, particularly in the treatment of interstitial lung disease. His innovative approaches aim to improve the quality of life for patients suffering from this challenging condition.

Latest Patents

Chunqin Deng holds a patent for a method of treating interstitial lung disease. This patent, which focuses on reducing pulmonary function decline and increasing forced vital capacity in affected subjects, involves the administration of treprostinil. His work in this area has the potential to transform treatment protocols for patients with interstitial lung disease.

Career Highlights

Deng is currently associated with United Therapeutics Corporation, where he continues to develop and refine his innovative treatment methods. His dedication to advancing medical science is evident in his research and the practical applications of his inventions.

Collaborations

Chunqin Deng collaborates with notable colleagues, including Leigh Peterson and Peter Smith. Their combined expertise enhances the research and development efforts at United Therapeutics Corporation.

Conclusion

Chunqin Deng's contributions to the treatment of interstitial lung disease exemplify the impact of innovation in medicine. His work not only addresses critical health challenges but also paves the way for future advancements in patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…